Iovance Biotherapeutics Inc IOVA 深 滬
已收盤 09-26 16:00:00 美东时间
2.11
+0.090
+4.46%
華盛通- 最 高2.11
- 今 開2.04
- 成交量 1018.09万股
- 最 低 1.9807
- 昨 收 2.02
- 總市值 7.64亿
- 52周最高 12.505
- 市盈率 靜 --
- 換手率 2.81%
- 52周最低 1.6385
- 委 比 -42.76%
- 總股本 3.62亿
- 歷史最高 54.208
- 量 比 0.90
- 振 幅 6.40%
- 歷史最低 1.6385
- 每 手 1
- 風險率 3.09%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Advancing Cancer Research Brings New Hope for Patients Worldwide
NetworkNewsWire Editorial Coverage NEW YORK, Sept. 17, 2025 /PRNewswire/ -- Progress in RNA-based medicines, immunotherapies and targeted treatments is not simply desirable, it is a critical...
09-17 20:30
Keurig Dr Pepper, Valneva, Venu Holding And Other Big Stocks Moving Lower On Monday
U.S. stocks were mixed, with the Dow Jones index falling more than 200 points o...
08-26 00:02
Iovance Biotherapeutics Amends Sale Agreement with Jefferies
The latest update is out from Iovance Biotherapeutics ( ($IOVA) ). On August 22...
08-23 05:50
Iovance Biotherapeutics Gains Health Canada Approval
Iovance Biotherapeutics ( ($IOVA) ) has shared an update. On August 18, 2025, I...
08-20 05:19
美股机会日报 | 重磅！特朗普正接受福克斯采访；获软银注资20亿美元，英特尔盘前涨超5%
重磅！特朗普正接受福克斯采访；获软银注资20亿美元，英特尔盘前涨超5%；担忧美股科技股暴跌？交易员抢购“灾难”看跌期权！详情>>
08-19 20:19
HC Wainwright & Co. Reiterates Buy on Iovance Biotherapeutics, Maintains $20 Price Target
HC Wainwright & Co. analyst Joseph Pantginis reiterates Iovance Biotherapeutics (NASDAQ:IOVA) with a Buy and maintains $20 price target.
08-19 19:06
美股盘前 | 财报超预期！派拓网络涨近6%；部分中概盘前走强，知乎涨超11%
财报超预期！派拓网络涨近6%；部分中概盘前走强，知乎涨超11%；加密货币走弱，Bullish跌约3%>>
08-19 16:15
盘前异动｜英特尔涨超6%，AEye涨超15%，Iovance飙升20%，Palo Alto Networks绩后涨超5%
8月19日，美股三大股指期货下跌，截止发稿，道指期货跌0.10%，纳指期货跌0.09%，标普500指数期货跌0.12%。 英特尔盘前涨超6%，软银集团与...
08-19 16:06
Iovance gets conditional Health Canada approval for Amtagvi
Iovance Biotherapeutics (NASDAQ:IOVA) shares rose post market after it received Health Canada approval with conditions for its T-cell immunotherapy, Amtagvi (lifileucel), as a treatment of advanced me...
08-19 05:00
Iovance Biotherapeutics Receives Health Canada NOC/c For Amtagvi
First T cell therapy for a solid tumor cancer and first treatment option approved in Canada for advanced melanoma after anti-PD-1 and targeted therapySAN CARLOS, Calif., Aug. 18, 2025 (GLOBE NEWSWIRE) -- Iovance
08-19 04:24
